UroGen Pharma Ltd.
URGN
$47.11
$0.801.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -97.64M | -133.23M | -153.49M | -164.64M | -154.97M |
| Total Depreciation and Amortization | 2.64M | 2.57M | 2.41M | 2.04M | 1.67M |
| Total Amortization of Deferred Charges | -774.00K | -774.00K | -774.00K | -774.00K | 738.00K |
| Total Other Non-Cash Items | 23.42M | 22.45M | 18.67M | 22.30M | 20.84M |
| Change in Net Operating Assets | -86.57M | -56.75M | -29.26M | 3.34M | 8.59M |
| Cash from Operations | -158.92M | -165.74M | -162.44M | -137.74M | -123.13M |
| Capital Expenditure | -218.00K | -299.00K | -289.00K | -387.00K | -396.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 40.32M | 67.13M | 61.85M | 94.85M | -43.29M |
| Cash from Investing | 40.10M | 66.83M | 61.56M | 94.46M | -43.69M |
| Total Debt Issued | 65.35M | 65.35M | -- | 0.00 | 24.49M |
| Total Debt Repaid | -2.56M | -2.18M | -1.86M | -- | -- |
| Issuance of Common Stock | 42.51M | 41.92M | 41.77M | 8.67M | 15.52M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.00K | 0.00 | 0.00 | 3.00K | 3.00K |
| Cash from Financing | 105.29M | 105.09M | 39.92M | 8.67M | 40.01M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.53M | 6.19M | -60.97M | -34.60M | -126.81M |